Human Papillomavirus Testing Market

Human Papillomavirus Testing Market Outlook (2024 to 2034)

The human papillomavirus (HPV) testing market size is estimated to be valued at US$ 1,214.0 million in 2024. The market is expected to expand at a CAGR of 10.3% through 2034. Anticipated growth is set to propel the market to an impressive size of US$ 3,236.3 million by 2034. Increasing awareness, rising incidences of HPV-related cancer, and advancements in testing technologies are driving the growth in the HPV testing market.

Global HPV testing market generated an estimated revenue of US$ 761.0 million in 2019. In five years, the market grew at a CAGR of 9.79% and added a staggering revenue of US$ 453 million. Several growth factors can be attributed to the market’s progress:

• The rising prevalence of human papillomavirus infections, particularly in sexually active populations
• Increased awareness about the link between persistent HPV infections and the development of cervical cancer, leading to a higher adoption of screening programs
• Ongoing advancements in diagnostic technologies, including more sensitive and specific HPV testing methods and improved accuracy of detection
• The emphasis on preventive healthcare, including routine screenings and early detection of potential health risks
• Supportive government initiatives to combat cervical cancer, including the promotion of HPV vaccination and routine testing
• The global increase in cervical cancer cases, often linked to persistent HPV infections, driving the need for more extensive screening and monitoring
• Continuous innovations in testing platforms and techniques, such as molecular diagnostics and DNA testing, enhancing the precision and efficiency of HPV testing

Apart from these factors, several other factors have contributed to the remarkable expansion of the human papillomavirus testing market. Increased healthcare expenditure by developing and developed economies has enabled better access to HPV testing services. The aging population in countries like Japan, Germany, and other countries, which are more susceptible to HPV-related complications, has contributed to the overall growth of the HPV testing market.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 1,214.0 million
Forecasted Market Value (2034F)	US$ 3,236.3 million
Global Market Growth Rate (2024 to 2034)	10.30% CAGR
DNA-based Test Segment Growth Rate (2024 to 2034)	11.10%
Hospitals Segment Growth Rate (2024 to 2034)	11.00%
North America Market Share (2024)	33.4%
East Asia Market Share (2024)	20.4%
Key Companies Profiled	Hologic Quest Diagnostics Abbott Laboratories Becton Dickinson & Company Onco Health Corporation Arbor Vita Corporation Femasys, Qiagen N.V. Seegene Mylab Discovery Solutions Pvt. Ltd.

Which Factors are Surging the Demand for Human Papillomavirus Testing?

“Rising Prominence of HVP in Sexually Active Populations”

The last few years have seen a tremendous surge in HVP incidences, especially among the younger population. This has drastically skyrocketed the demand for HPV testing kits and campaigns. HPV’s association with cervical cancer is one of the main reasons for the exponential expansion of the market. Increasing recognition of HPV as a common and potentially harmful infection has also pushed individuals to seek testing for early detection and intervention, further escalating the market valuation.

Apart from this, public health campaigns and educational initiatives have also played an important role in spreading information about the risks associated with untreated HPV infections. This has been one of the most crucial drivers for the growth of the HPV testing market. Campaigns by public and private sectors have resulted in an increased number of tests, especially in the women demographic. All these factors have collectively led to a surge in the demand for HPV testing.

“Advancements in HPV Testing Technologies and Supportive Government Initiatives”

Ongoing developments in diagnostic methods have resulted in the introduction of more sensitive and specific HPV testing technologies. This has resulted in enhancing the overall accuracy of detection. Individuals across the world are preferring these new methodologies as they eliminate the challenges of false negatives and false positives, providing them with more reliable test results. This has gradually increased the trust among the individuals, further augmenting the market growth.

Government initiatives have also been instrumental in the promotion of comprehensive healthcare strategies aimed at preventing human papillomavirus. Many governments worldwide have implemented proactive screening programs and health campaigns, temporary testing centers, etc., to reduce the incidence of HPV-induced cervical cancer and its associated morbidities and mortality. This has significantly contributed the overall market for HPV testing.

What is Restraining the Human Papillomavirus Testing Market?

“Limited Awareness, Stigma and Sociocultural Factors, and High Cost of Tests”

Despite awareness initiatives by the public as well as private healthcare institutions, there may still be gaps in knowledge regarding HPV and the importance of testing in the general population. This results in lower demand for HPV testing services, particularly in regions where education on sexual health is inadequate. Besides this, stigma associated with sexually transmitted infections also hinders individuals from seeking doctor’s advice. This is one of the main challenges slowing down the market growth. The cost of HPV testing and limited access to healthcare services, particularly in regions with low per capita income, creates challenges in the market in certain areas.

Country-wise Insights

The North American human papillomavirus testing market is poised for exceptional growth, projecting a modest CAGR of 9.6% through 2034. The surge is primarily attributed to the increasing demand for human papillomavirus testing in key countries, notably the United States and Mexico.

In 2024, the United States dominates the human papillomavirus testing industry with an estimated 74.9% market share. Meanwhile, the East Asian human papillomavirus testing market is anticipated to exhibit substantial progress, aiming for a 12.8% CAGR through 2034. In this region, Japan emerges as the key player in the industry, commanding a significant share of 49.6% in 2024.

Why is the United States Leading the Human Papillomavirus Testing Market in the North American Region?

“Robust Diagnostic Capabilities Coupled with Public Health Initiatives and Awareness Campaigns”

Attribute	Details
Market Value in 2024	US$ 304 million
CAGR (2024 to 2034)	9.7%

The North American market stood at US$ 405 million in 2024, acquiring a revenue share of 33.40%. This is further projected to expand at a CAGR of 9.6% through 2034. The United States human papillomavirus testing industry is estimated to be worth US$ 304 million in 2024. The demand for human papillomavirus testing in the United States is projected to rise at a CAGR of 9.7% through 2034.

The United States is blessed with an advanced healthcare system with robust diagnostic capabilities. The country has a well-established network of healthcare facilities, laboratories, and diagnostic centers equipped with modern technologies for HPV testing. This kind of infrastructure has facilitated widespread access to testing services. This has enabled a larger portion of the population to undergo HPV screenings. Apart from this, comprehensive strategies to educate the public about the risks of HPV infections by government as well as private healthcare entities have led to sustained growth in the HPV testing market in the United States.

Why is the Demand for Human Papillomavirus Testing Increasing in Japan?

“Preventive Healthcare Culture and Research and Development Activities in the Healthcare Sector to Boost Market Expansion”

Attribute	Details
Market Value in 2024	US$ 123 million
CAGR (2024 to 2034)	13.8%

The Japanese human papillomavirus testing industry is estimated to be worth US$ 123 million in 2024, garnering a share of 87.7% of the East Asian region. The sales of human papillomavirus testing are likely to grow at a CAGR of 13.8% through 2034.

Japan has a strong emphasis on preventive healthcare. The general population in Japan undergoes regular health check-ups and screenings, including HPV testing. This can lead to early detection of fatal diseases like HPV. Another major driver for the growth of the HPV testing market in the Japanese demographic is the aging population. The chances of getting diagnosed with HPV are more in this age group, which is leading to an increased number of tests in the country.

Category-wise Insights

The DNA-based test segment is estimated to hold a 61.0% of human papillomavirus (HPV) testing market share in 2024 based on the product. Simultaneously, the molecular segment is anticipated to secure a noteworthy share of 92.2%, contributing significantly to the market's resource diversity and stability. Based on the end user, the hospital segment marks its dominance in the human papillomavirus testing industry, with a share of 51.9% in 2024.

Why are DNA-based HPV Testing Solutions Gaining Popularity in the Healthcare Sector?

“Enhanced Sensitivity, Specificity and Early Detection of Infection in DNA-based Tests”

Attribute	Details
Market Share in 2024	61.0%

The demand for human papillomavirus testing solutions in biologics is experiencing a tremendous surge as it offers enhanced sensitivity and specificity in detecting HPV infections. This heightened accuracy is crucial in identifying high-risk HPV strains that are strongly linked to the development of cervical cancer. As a result, healthcare providers and professionals are increasingly turning to DNA-based HPV testing solutions for more precise and reliable results.

The demand for DNA-based HPV testing is also touching the skies as it provides the advantage of early detection and risk stratification. These tests can identify the presence of the virus and its specific genotype, allowing healthcare professionals to assess the level of risk associated with persistent infections. All these factors have collectively increased the popularity of DNA-based HPV testing in the general population.

Competitive Landscape

The global human papillomavirus testing market is filled with a multitude of companies, such as Hologic, Quest Diagnostics, Abbott Laboratories, Becton Dickinson & Company, etc. These companies have a well-established consumer base which is spread across the globe. Companies in this market cater to hospitals, research institutes, diagnostic centres, etc.

Several small companies are present in the market. These companies play a crucial role in shaping industry trends through innovations in testing technologies, strategic partnerships, and participation in government-sponsored screening programs.

• In March 2023, The International Agency for Research on Cancer (IARC) marked International Human Papillomavirus (HPV) Awareness Day by launching a new online guide, an IARC atlas aiding health professionals in utilizing HPV tests for cervical cancer screening and managing HPV-positive women.
• Recently, Abbott secured U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus (HPV) screening solution, enhancing the Alinity m diagnostic assay family with a potent cancer screening tool.
• India recently received the first at-home self-test kit for women to screen for Human Papillomavirus (HPV), the major cause of cervical cancer. LifeCell, a renowned stem cell bank, offered the at-home vaginal swab test at Rs. 2,500 per test.

Key Segments Covered in the Human Papillomavirus Testing Industry

• By Product:

  • DNA-based Test
  • RNA-based Test

• By Application:

  • Molecular Diagnostics
  • Research Use

• By End User:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Research Institutes

• By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa